Morningstar, Inc.
http://www.morningstar.com/Morningstar, Inc. (MORN) is an independent investment research company that provides data on more than 125,000 investment offerings, including stocks, mutual funds, and ETFs. The company offers its products and services through the Internet, software, and print for individuals, financial advisors, and institutions. The firm was founded in 1984 and is headquartered in Chicago, IL.
View Older Stories View More Recent Stories
-
Australia's WiseTech shares jump after CEO White takes on new role
-
Federated Hermes, Inc. reports record assets under management with third quarter 2024 earnings
-
BlackRock Introduces Three iShares ETFs to Customize Exposure to U.S. Large Caps
-
Tesla rallies most in over a decade on Musk's bold EV forecast
-
Form 8-K Morningstar, Inc. For: Oct 23
-
Morningstar (MORN) Reports In-Line Q3 EPS
-
Morningstar (MORN) Chief Financial Officer Jason Dubinsky to Depart
-
Morningstar Chief Financial Officer Jason Dubinsky to Depart
-
Morningstar, Inc. Reports Third-Quarter 2024 Financial Results
-
Ameriprise Financial Reports Third Quarter 2024 Results
-
Seven & i aims to convince investors it can deliver on its own
-
HSBC CEO tells staff senior redundancies inevitable after revamp
-
Orrstown Financial Services, Inc. Reports Third Quarter 2024 Results
-
Asana Announces AI Studio: No-Code Builder for Designing and Deploying AI Agents in Critical Workflows
-
Analysis-Investors flee thematic ETFs as stock benchmarks soar
-
Analysis-Investors flee thematic ETFs as stock benchmarks soar
-
eQ Plc’s interim report Q3 2024 – eQ’s operating profit EUR 27.6 million
-
Volta Finance Limited - Net Asset Value(s) as at 30 September 2024
-
Columbia Research Enhanced Core ETF (RECS) Celebrates Five-Year Anniversary, $1B AUM Milestone
-
Netflix hits record high as strong subscriber additions ease growth worries
-
Star Entertainment reverses course a day after Sydney casino relief
-
Adams Diversified Equity Fund Reports Nine Month Results
-
Christine Buck Awarded AMA Chicago’s 2024 'Marketer of the Year'
-
Sienna Announces Completion of $150 Million Offering of 4.436% Series D Senior Unsecured Debentures
-
PPG to lay off 1,800 employees in cost-cut drive, sell coatings unit
-
China boosts funds for housing projects to support embattled sector
-
Kiavi closes $400 million rated securitization of residential transition loans, its 20th transaction in five years
-
CLUB® CRACKERS UNVEILS A FIRST-OF-ITS-KIND SWEET HAWAIIAN CRACKER
-
Kellanova & The Global FoodBanking Network Partner to Ensure Better Days for Children
-
ESG Risk Rating 2024: Techem achieves top ranking again
-
Real Estate Fintech Backflip Announces $184 Million of Capital to Finance ‘Value-Add’ Residential Investments
-
ING completes share buyback programme
-
UAE WEB3FEST 2024: Discover Tomorrow, Today in the Heart of the Middle East’s Web3 Revolution.
-
Analysis-7-Eleven's turnaround plan requires heavy lifting to stop Couche-Tard's $47 billion takeover
-
NSF Welcomes Mel Cash as Chief Commercial Officer
-
US credit spreads narrow to new lows as economy looks up
-
Proposed Merger and Offer
-
Kellanova Has it All This Fall: Flavor and Fun with Satisfying Snacks and a Toasty Halloween Costume
-
Morningstar DBRS cuts estimate for Milton insured losses to $30-60 billion
-
Battered Florida begins long recovery from back-to-back major hurricanes
-
Gateway Equity Call Premium Fund (GCPYX) Celebrates Ten Years
-
New Schwab Asset Management Study: ETF Investors Keep Calm and Carry On Amid Market and Political Uncertainty
-
Maanch Introduces Groundbreaking ESG Engagement Innovation
-
Starlight Capital Launches New Starlight Dividend Growth Class ETF (SCDG)
-
Piper Sandler Reiterates Underweight Rating on Beyond Meat Inc. (BYND)
-
PRINGLES® EMBRACES THE NATION'S LATEST FOOD OBSESSION WITH THE RETURN OF PRINGLES DILL PICKLE
-
Luxury goods unlikely to be next target of China's EU trade retaliation, analysts say
-
Hurricane Milton could cost insurers up to $100 billion, analysts say
-
Redburn-Atlantic Downgrades Morningstar (MORN) to Neutral
-
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with KEYTRUDA® (pembrolizumab)

